Mennitto Alessia, Verzoni Elena, Grassi Paolo, Ratta Raffaele, Fucà Giovanni, Procopio Giuseppe
a Department of Medical Oncology , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1395-1402. doi: 10.1080/17512433.2017.1386552. Epub 2017 Oct 6.
in the last decades, the treatment of renal cell carcinoma has become more complex due to the introduction of novel systemic agents and the improvement of the loco-regional therapies that prolong survival maintaining a good quality of life. Areas covered: in this review, we summarize the currently available local and systemic treatment options, their indications and their hypothetical role in the management of advanced renal cell carcinoma, highlighting the need of multimodality treatment paradigms within interdisciplinary decision-making. Expert commentary: in early disease, radical or partial nephrectomy remains the standard of care, but innovative ablation techniques, including radiofrequency ablation, microwave ablation, cryoablation and so on, may represent an alternative option of treatment for small renal lesions in unfit patients who cannot undergo surgery. In metastatic setting, it is imperative a multidisciplinary team approach to select patients for a cytoreductive nephrectomy, metastasectomy, and/or systemic treatment, aiming to the optimization of the treatment strategy.
在过去几十年中,由于新型全身治疗药物的引入以及局部区域治疗的改进,肾细胞癌的治疗变得更加复杂,这些治疗延长了生存期并维持了良好的生活质量。涵盖领域:在本综述中,我们总结了当前可用的局部和全身治疗选择、它们的适应证以及它们在晚期肾细胞癌管理中的假设作用,强调了跨学科决策中多模式治疗模式的必要性。专家评论:在早期疾病中,根治性或部分肾切除术仍然是标准治疗方法,但创新的消融技术,包括射频消融、微波消融、冷冻消融等,可能是无法接受手术的不适合患者中小肾病变的替代治疗选择。在转移性情况下,必须采用多学科团队方法来选择适合进行减瘤性肾切除术、转移灶切除术和/或全身治疗的患者,旨在优化治疗策略。